Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01882582 · ClinicalTrials.gov registry record
Evaluation of Immune Signaling Networks in Healthy Human Volunteers
A clinical trial, sponsored by Martin Angst.
- Completed
- Registry status
- 25
- Enrollment target
NCT01882582: Completed study, sponsored by Martin Angst.
NCT01882582 is a clinical trial that has completed, run by Martin Angst. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01882582 has completed, sponsored by Martin Angst.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to better understand whether and to what extent the activity of immune cells in blood varies over time under normal conditions as assessed in healthy subjects. Results of this study will provide the foundation for helping us evaluate changes in immune cell activities in response to surgery and drugs used in anesthesia. The overall purpose of our research is to understand immune health in the context of anesthesia and surgery.
Primary Outcome
This is an exploratory study. Numerical and functional (phosphorylation of signaling molecules and transcription factors) behavior of all circulating immune cells will be captured. Blood specimens collected at referenced time points will be analyzed with mass cytometry.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-07 |
What the finished NCT01882582 record still lists
NCT01882582 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01882582 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01882582 about?
NCT01882582 is a clinical study titled "Evaluation of Immune Signaling Networks in Healthy Human Volunteers". The purpose of this study is to better understand whether and to what extent the activity of immune cells in blood varies over time under normal conditions as assessed in healthy subjects. Results of this study will provide the foundation for helping us evaluate changes in immune cell activities in ...
What is the current status of trial NCT01882582?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2012-08. Estimated completion is 2013-07.
Who is sponsoring clinical trial NCT01882582?
This trial is sponsored by Martin Angst, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia